Abstract：
HPV16 status in oropharyngeal cancer (OPC) is an important prognostic factor. Its determination, based on immunistochemical analysis of p16 oncoprotein requires an invasive biopsy. Thus, alternative methods are being sought. Determining oral HPV16 status appears to be a promising alternative. However, it is not used routinely. This prompted us to perform a systematic literature review enabling us to evaluate the diagnostic and predictive ability of this approach. Thirty-four relevant studies were finally selected. For determination of HPV status in OPC, the calculated average sensitivity and specificity for oral sampling was 74% and 91%, respectively, with p16 tumour tissue marker being the gold standard. The method appears to be valuable in monitoring treatment response as well as the biological activity of the tumour, enabling early detection of persistent or relapsing carcinoma sufficiently long before its clinical and/or radiological manifestation. It can also contribute to identification of the primary tumour in cases of metastases of unknown origin. Last but not least, the screening HPV oral testing would help to identify individuals with persistent HPV oral infection who are at increased risk of development of OPC.
摘要：
HPV16状态在口咽癌（OPC）中是一个重要的预后因素。它的决心，根据p16癌蛋白的免疫化学分析，需要进行侵入性活检。因此，正在寻找替代方法。确定口服HPV16状态似乎是一种有希望的替代方法。然而,它不是常规使用。这促使我们进行系统的文献综述，使我们能够评估这种方法的诊断和预测能力。最终选择了34项相关研究。为了确定OPC中的HPV状态，经计算，口腔取样的平均敏感性和特异性分别为74%和91%，分别,p16肿瘤组织标记是金标准。该方法在监测治疗反应以及肿瘤的生物活性方面似乎很有价值。能够在其临床和/或放射学表现之前足够长的时间内早期检测到持续性或复发性癌。它还可以有助于在未知来源的转移的情况下鉴定原发性肿瘤。最后但并非最不重要的,筛查HPV口腔检测将有助于确定患有持续性HPV口腔感染且发生OPC风险增加的个体.
